Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Clin Cancer Res. 2011 Aug 15;17(19):6239–6249. doi: 10.1158/1078-0432.CCR-11-1424

Figure 4. Performance of the miRNA-based predictor to distinguish the type of MSI.

Figure 4

A) Receiver operating curve of the miRNA-based predictor (miR-622, miR-362-5p, miR-486-5p) to distinguish the presence of Lynch syndrome among MSI tumors. S1, training set (n=14); S2, test set (n=33). B) Discriminant probability plot. The graphical representation shows the LOO-CV probabilities (0.0 to 1.0) of each tumor for being sporadic MSI (red dots and triangles) or Lynch syndrome (blue dots and triangles). Dots indicate samples from the training set (set 1) and triangles from the test set (set 2).

HHS Vulnerability Disclosure